NTHU
25.11.2021 11:02:06 CET | Business Wire | Press release
Japan has donated five batches of the AZ COVID-19 vaccine to Taiwan, and Taiwan has reciprocated by providing treatment at NTHU’s Boron Neutron Capture Therapy Center (BNCTC) for a 20-year-old Japanese woman suffering from a malignant brain tumor. The treatment was a success, and she has now returned to school.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211125005795/en/
The doctor in charge of the treatment was Yi-Wei Chen of the Oncology Department at Taipei Veterans General Hospital (TVGH). He said that only Taiwan and Japan have medical centers using boron neutron capture therapy (BNCT) to treat cancer. However, Japan’s Ministry of Health, Labor, and Welfare has not yet approved BNCT for treating malignant brain tumors, leaving Taiwan as the only source of treatment for malignant brain tumors that are difficult to treat by surgery.
Chen said that the Japanese patient was originally diagnosed with rhabdomyosarcoma of the right ear canal at the age of six. After surgery and chemotherapy, the condition was stable for a time. Unexpectedly, the tumor recurred in 2018, and the tumor metastasized to the hindbrain. After it was determined that it turned out to be malignant peripheral nerve sheath tumor, she received heavy particle and CyberKnife treatment in Japan, but the tumor still recurred.
Thus she decided to come to Taiwan for BNCT, and arrived in April 2021. By that time the tumor was 6–7 cm in size, but after the first round of irradiation at the THOR BNCT Cancer Center, it shrank by 80%, and the compression on her neck relieved considerably, much to the delight of the medical team, and she returned to Japan. However, at the end of July, some signs of recurrence were discovered, and she was advised to return to Taiwan for a second round of irradiation.
She went to the THOR BNCT Cancer Center for treatment on September 17. After the injection of the Boron-10 drug and a 20-minute session of neutron source irradiation, she had a group photo in front of the NSTDC with the medical team, who presented her with a teddy bear wearing a graduation cap, as a way of wishing her a speedy “graduation” from her cancer. Afterwards, she thanked the medical team in fluent English.
Working closely with the TVGH, the BNCTC has treated over one hundred patients from all over the world, including Spain, Brazil, Australia, Singapore, Japan, and China.
BNCT is a kind of targeted radiotherapy in which the patient is first injected with a boron-containing drug; once the drug has accumulated in the tumor, the neutron beam from the nuclear reactor is used to irradiate the tumor, and the high-energy particles generated by the boron neutron capture reaction effectively kill off the tumor cells, without damaging nearby normal cells. Thus BNCT is well suited for treating diffuse cancers and cases in which surgery is contraindicated.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211125005795/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Venture Global and China Gas Announce New Long-Term LNG Agreement14.9.2026 10:30:00 CEST | Press release
Today, Venture Global, Inc. (“Venture Global”; NYSE: VG) and China Gas Holdings Limited (“China Gas”; stock code: 0384.HK), a leading natural gas operator in China, announced the execution of a new Sales and Purchase Agreement (SPA) for the purchase of 0.5 million tonnes per annum (MTPA) of U.S. liquefied natural gas (LNG) from Venture Global for twenty years starting in 2030.This SPA brings Venture Global’s current long-term offtake with China Gas, to 2.5 MTPA under 20-year SPAs supplied across Venture Global’s portfolio. "Venture Global is pleased to expand our LNG partnership with China Gas, a leading natural gas operator in China, supplying the country's growing energy needs with reliable, low-cost American LNG from across our Louisiana projects," said Venture Global CEO Mike Sabel. “We are pleased to deepen our long-standing partnership with Venture Global through this new agreement,” said Mr. Liu Ming Hui, Chairman and President of China Gas. “It further strengthens our portfolio
Thales Builds Cryptographic Security for the Age of AI and Post-Quantum Computing14.9.2026 09:00:00 CEST | Press release
Thales launches Luna 8, a new hardware security module (HSM) to provide future-ready, quantum resistant security to protect critical data and applications Powered by a Thales designed cryptographic processor, it delivers unparalleled performance, enhanced protection and the flexibility to adapt to new security needs Drawing on decades of cryptographic expertise, Luna 8 combines trusted security with support for emerging technologies, including post quantum cryptography According to the 2026 Thales Data Threat Report, the threat of Harvest Now, Decrypt Later (HNDL) attacks was the top-cited risk, with 59% of organizations reporting that they are prototyping and evaluating post-quantum cryptography (PQC) algorithms to prepare for the quantum era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804748922/en/ ©Thales To help organizations turn this readiness into deployment,Thales, a global leader in advanced technologies, tod
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations14.9.2026 09:00:00 CEST | Press release
Acceptance is based on pivotal Phase 3 data demonstrating rapid, durable and consistent skin clearance, including in high-impact sites, in a convenient once-daily pill Results from nearly 3,000 patients support potential for next-generation TYK2 inhibitor to redefine oral treatment expectations in psoriasis The Prescription Drug User Fee Act (PDUFA) target action date is in the first quarter of calendar year 2027 Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib is an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, which demonstrated rapid, durable and consistent skin clearance in Phase 3 plaque psoriasis studies.1-3 Addressing unmet needs in psoriasis treatment “Despite progress in psoriasis care, there remains a need for highly
SWISSto12 and Mitsubishi Electric Corporation Announce Strategic Partnership14.9.2026 09:00:00 CEST | Press release
The Memorandum of Understanding (MoU) and additional contract signal a new phase of collaboration on market development in the Asia Pacific (APAC) region SWISSto12 today announced a memorandum of understanding (MoU) with Mitsubishi Electric Corporation (MELCO) (TOKYO: 6503) to pursue joint opportunities on advanced payloads, radio frequency (RF) products, and market development in Japan and the APAC region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914982179/en/ Masahiko Arai, Executive Officer and Group President, Defense & Space Systems, Mitsubishi Electric, and Dr. Emile de Rijk, Chief Executive Officer, SWISSto12 Joint opportunities will leverage MELCO’s extensive satellite system expertise and integration capabilities together with SWISSto12’s proprietary 3D-printing designs and processes that form the foundation of its next-generation payloads—smaller, lighter, highly performant, yet built in materially shorter
Focused Support Launches Cavok STRIKE to Expand Link-16 Participation Across the Joint Force14.9.2026 07:00:00 CEST | Press release
Extending Link-16 interoperability without platform-level hardware integration Focused Support LLC today announced the launch of Cavok STRIKE, an integrated software capability that expands the Link-16 tactical battlespace picture by enabling additional operational platforms to participate in the Link-16 network. Modern battlefields have increasing numbers of unmanned systems, sensors, and supporting platforms operating throughout the joint battlespace. The rapid proliferation of Group 1, 2, and 3 UAS, including both expendable and recoverable systems, has created a growing need to integrate these assets into the broader tactical network. Many of these platforms provide operationally relevant information but have historically remained outside the Link-16 network due to limitations in size, weight, power, platform integration complexity, or acquisition cost. Cavok STRIKE addresses this gap by enabling platforms to participate in the Link-16 network as non-command-and-control participant
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom